质子放疗再照射的临床结局与毒性系统评估
结果显示质子再照射总体安全性突出,再复发 salvage 有效,但现有数据有限,需继续报告机构经验、剂量学相关性、晚期毒性和先进质子技术。
要点
- 质子再照射在复发葡萄膜黑色素瘤5年保眼率55%,脊索瘤2年局控85%、OS 80%。
- 成人胶质瘤质子再照射多项研究未报告≥3级毒性;儿童CNS肿瘤再照射安全有效。
- 头颈肿瘤质子再照射局控/区域控良好,喂养管置入率低(9-10%)。
核心结论
- 基于有限现有数据,质子束放疗是再照射中显著安全的模式,可有效挽救复发疾病。
主要发现
- 复发葡萄膜黑色素瘤质子再照射5年保眼率为55%。
- 脊索瘤质子再照射2年局部控制率和总生存率分别为85%和80%。
- 成人胶质瘤多项质子再照射研究未报告≥3级毒性。
- 两项儿童中枢神经系统肿瘤研究显示再照射安全有效,共1例3级毒性,并获得较长总生存。
- 头颈肿瘤质子再照射显示适当的局部/区域控制及较历史光子方法更有利的毒性特征,喂养管置入率低(9-10%)。
关键数值与推荐
- 复发葡萄膜黑色素瘤质子再照射5年保眼率55%。
- 脊索瘤质子再照射2年局部控制率85%、总生存率80%。
- 头颈肿瘤质子再照射喂养管置入率9-10%。
临床怎么用
- 质子再照射可用于中枢神经系统、头颈、肺和消化道复发肿瘤的挽救治疗,尤其适合需保护正常组织的再照射场景。
- 头颈肿瘤质子再照射可能降低喂养管依赖,优于历史光子方法。
- 肺复发肿瘤质子再照射尤其同步化疗和中央型复发时,可获有利生存并出现再照射预期毒性/并发症。
局限性
- 现有数据有限。
- 需继续报告机构经验、剂量学相关性、晚期毒性和先进质子技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reirradiation (reRT) for locoregional recurrences poses unique challenges and risks; re-treatment using proton beam radiotherapy (PBT) could prove advantageous. Assessing clinical outcomes and toxicity profiles, this systematic review comprehensively evaluated available evidence regarding PBT reRT. Fourteen original investigations across central nervous system (CNS) (n=6), head/neck (H&N) (n=4), lung (n=2), and gastrointestinal (n=2) malignancies were analyzed. PBT for recurrent uveal melanoma achieved 5-year eye retention of 55%; for chordomas, reRT afforded a 2-year local control and overall survival (OS) of 85% and 80%, respectively. Multiple PBT reRT studies for adult gliomas illustrate no grade ≥3 toxicities. Two pediatric CNS tumor studies demonstrated the safety and efficacy of reRT, with one total grade 3 toxicity and achievement of longer-term OS. PBT for H&N malignancies shows appropriate local/locoregional control and favorable toxicity profiles versus historical photon-based methods, including low (9-10%) rates of feeding tube placement. PBT for recurrent lung cancer can achieve favorable survival with expected toxicities/complications of reRT, especially with concurrent chemotherapy and centrally located recurrences. Lastly, PBT reRT in gastrointestinal malignancies induced very few high-grade complications. Hence, based on the limited existing data, PBT is a notably safe reRT modality for effective salvage of recurrent disease. Institutional experiences must continue to be reported: dosimetric correlations, late toxicities, and advanced PBT techniques.
引用
- Verma V, Rwigema JM, Malyapa RS, et al. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol. 2017. PMID: 28941560. doi:10.1016/j.radonc.2017.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。